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P E R S P E C T I V E
Identifying key questions in the ecology and evolution of 
cancer
Abstract
The application of evolutionary and ecological principles 
to cancer prevention and treatment, as well as recognizing 
cancer as a selection force in nature, has gained impetus 
over the last 50 years. Following the initial theoretical ap-
proaches that combined knowledge from interdisciplinary 
fields, it became clear that using the eco- evolutionary 
framework is of key importance to understand cancer. We 
are now at a pivotal point where accumulating evidence 
starts to steer the future directions of the discipline and 
allows us to underpin the key challenges that remain to be 
addressed. Here, we aim to assess current advancements 
in the field and to suggest future directions for research. 
First, we summarize cancer research areas that, so far, 
have assimilated ecological and evolutionary principles into 
their approaches and illustrate their key importance. Then, 
we assembled 33 experts and identified 84 key questions, 
organized around nine major themes, to pave the founda-
tions for research to come. We highlight the urgent need 
for broadening the portfolio of research directions to stim-
ulate novel approaches at the interface of oncology and 
ecological and evolutionary sciences. We conclude that 
progressive and efficient cross- disciplinary collaborations 
that draw on the expertise of the fields of ecology, evolu-
tion and cancer are essential in order to efficiently address 
current and future questions about cancer.
1  | INTRODUC TION
The application of evolutionary and ecological principles to preventing 
and treating cancer (Gatenby & Brown, 2018), as well as to under-
standing the impact of cancer on organismal health, fitness, species 
stability and ecosystem functioning (Thomas et al., 2017), has been 
gaining increasing attention and recognition among both oncologists 
and biologists since the seminal work of Cairns (1975), Nordling 
(1953) and Nowell (1976), more than 45 years ago. Most scientists 
today agree that this evolutionary view has deeply transformed the 
way we understand the biology of cancer— explaining its origin and 
the recrudescence of cancer cells as well as elucidating reasons for 
therapy failures. Following the theoretical development of a new 
interdisciplinary field that combines expertise from mathematicians, 
data scientists and biostatisticians, geneticists, evolutionary biologists, 
ecologists, physicists and oncologists, we are now at a pivotal point 
where empirical data and evidence are accumulating and guiding fu-
ture directions of the discipline (Ujvari et al., 2017). We believe that 
the time has arrived to take stock of current advancements and to 
inform the course of future research. Cancer is a disease that impacts 
every country worldwide (18.1 million new cases and 9.6 million death 
in 2018; Bray et al., 2018), and these oncogenic processes are an inev-
itable phenomenon of metazoan life. Identifying the key questions in 
the ecology and evolution of cancer will provide a cornerstone in can-
cer and evolutionary research for the coming years. This will provide 
the basis for the development of efficient strategies to either prevent 
cancer evolution or improve treatment of even advanced cancers.
A recently published viewpoint article presents a valuable road-
map for the next decade in cancer research (Bernards et al., 2020). 
However, this roadmap, based on the opinion of 10 researchers, does 
not mention how the ecological and evolutionary theory, principles 
and approaches have already provided major and novel insights into 
our understanding of several cancer- related topics, nor provides fu-
ture avenues of research studying cancer with an evolutionary bi-
ology approach. Below, we first summarize the main cancer- related 
areas that benefited from applying ecological and evolutionary 
thinking. Then, we identified and highlighted key questions, and or-
ganized around nine major themes based on the systematic classifi-
cation and ranking of the feedback obtained from the 33 scientists 
that contributed to this study (see section 2).
1.1 | Cancer as a complex eco- evolutionary process
Neoplasia has been detected in most multicellular groups, suggest-
ing that its evolutionary roots can be traced back to the evolution 
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of multicellularity (Ackermann, 2015). In fact, cancer is often seen 
as a by- product of multicellularity, specifically a breakdown of the 
mechanisms that evolved to ensure the functionality of the newly 
emerged multicellular individual by promoting cooperation among 
constituent cells (Aktipis et al., 2015). In this framework, cancer 
cells are selfish/cheater cells whose success is dependent on the 
failure of the multicellular organisms to suppress, detect and police 
them (Aktipis et al., 2015; Aktipis, 2020). Differences in the pro-
pensity to develop cancer among species can thus be understood 
not only as the result of differences in mutation hazard (intrinsic 
or extrinsic) but also as the result of differences in the ability to 
prevent and deal with such selfish mutants (i.e. differences in tu-
mour suppression mechanisms). Following the acknowledgement 
that oncogenic processes are inevitable phenomena in all meta-
zoans since the dawn of multicellularity, the field of comparative 
oncology— the study of oncology in non- human organisms— has 
brought relevant insights into how biological, genetic and ecologi-
cal factors drive individual and species variations in cancer diver-
sity, incidence, therapy resistance and lethality. As such, it opens 
the opportunity to develop a universal theory of cancer biology 
that promises to revolutionize conventional preclinical models and 
cancer treatment strategies (Albuquerque et al., 2018; Somarelli 
et al., 2020).
1.2 | Understanding cancer's evolutionary history
Each of the nearly 10 million people dying from cancer every year 
developed that lethal cancer de novo (Bray et al., 2018; Pienta et al., 
2020; Siegel et al., 2018). Over the last 50 years, a series of mutually 
non- exclusive but concurrent theories have been put forward to ex-
plain the initiation and progression of cancer. (a) The classic model of 
stepwise carcinogenesis, first proposed by Nordling (Nordling, 1953) 
in 1953 and then by Nowell (1976) in 1976, posits that a transformed 
cell gains unlimited proliferative capacity and uncontrolled cell 
growth via subsequent accumulation of random mutations. Once a 
heterogeneous cell subpopulation is initiated within the tissue en-
vironment, natural selection favours cancer cells harbouring muta-
tions that confer higher fitness, making these cell clones the most 
prominent in the population. The recurring cycles of clonal sweeps 
lead to cancer growth, progression and dispersal (i.e. metastasis). 
(b) Similar to the classic model, the hierarchical model (Costa et al., 
2006; Wicha et al., 2006) also traces tumour origins to single mu-
tated cells with unlimited proliferative potential, but assumes that 
the development of the tumour results from the clonal evolution of 
cells with stem cell properties (Lapidot et al., 1994; Sell, 1993; Tan 
et al., 2006; Visvader & Lindeman, 2008). Independent of the type of 
cancer progenitor cells (i.e. somatic cells or cancer stem cells), both 
theories portray cancer progression as the accumulation of genetic 
modifications (mutations and epigenetic alterations) and expansion 
of clones with higher fitness.
While the early models proposed gradual accumulation of 
genomic alterations to acquire the selective advantages by the 
malignant cells (Fearon & Volgelstein, 1990), later, karyotype- 
based studies suggested a stochastic cancer evolution model, 
with cancer cell populations alternating between punctuated 
(rapid, stochastic karyotype changes) and sequential phases 
(subsequent clonal expansion of cancer cells) (Yates & Campbell, 
2012).
The study of metastasis has also benefited from eco- evolutionary 
thinking. The movement of malignant cells from the primary tumour 
to a secondary site in the host's body is likely in response to the 
selective pressure within the tumour microenvironment, including 
resource scarcity, increased risk of death and overcrowding (Aktipis 
et al., 2012; Chen et al., 2011). While being highly risky, this migra-
tion significantly increases the fitness of malignant cells, which al-
lows scientists to draw parallels with the way animals migrate and 
disperse to increase their fitness (Aktipis et al., 2012; Chen et al., 
2011; Tissot et al., 2019).
In 1889, Steven Paget proposed the ‘Seed and Soil’ hypothesis, 
introducing the concept that a receptive microenvironment was re-
quired for malignant cells to engraft distant tissues and form metas-
tases (Paget, 1889). It is now well established that the processes of 
clonal cell expansion, diversification and selection that characterizes 
malignant tumour evolution occur within the tissue ecosystem and 
microenvironment, and include the selective pressure generated 
by the treatment which contributes for the selection of resistant 
variants (Chen & Pienta, 2011). Cancer cells themselves alter their 
microenvironment to their own benefit, by promoting angiogene-
sis, changing the functions of stromal cells, inducing neural damage, 
neutralizing immune cells and promoting an immunosuppressive en-
vironment (Costa et al., 2018).
1.3 | Applying eco- evolutionary principles to 
manage and treat cancer
Theodosius Dobzhansky famously stated that ‘nothing in biology 
makes sense except in the light of evolution’ (Dobzhansky, 1973). The 
emergence of cancerous cells can be seen as a speciation event, in 
which a new parasitic species emerges, initiates a clade and consumes 
resources from the host, impairing the host's health and decreasing its 
fitness (Capp & Thomas, 2020; Duesberg et al., 2011). When a cancer 
emerges, its progression is then governed through Darwinian selection 
(referred as somatic evolution) that is separate from the host (the unit 
of natural selection). In addition, a tumour can be considered as being 
a whole ecosystem in which cells adapt and evolve to exploit the re-
sources of the environment or to develop resistance to drug treatment 
(Aktipis & Nesse, 2013; Gatenby & Brown, 2018; Nowell, 1976). It is 
therefore of key importance to understand the coevolutionary dynam-
ics of cancer functioning to design efficient treatments and improve 
the outcome of patients. Such understanding may be enhanced by ex-
tending concepts (e.g. commensalism, parasitism, predation, ecologi-
cal niche, selective pressure) or tools such as population dynamics or 
game theory models widely used in ecology (Archetti & Pienta, 2019; 
Dhawan et al., 2016; Maley et al., 2017) to treatment approaches and 
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strategies. Adaptive therapy, in which cancer is treated by alternating 
different drugs to avoid selection for resistant cancer cells, is a primary 
example of the successful application of the theory of evolution in can-
cer treatment (Gatenby et al., 2009).
1.4 | A general view on the interaction between 
species evolution and cancer incidence
Oncogenic processes, and the resulting selection of costly host de-
fences yielding to trade- offs, have been a major force shaping eco-
logical and evolutionary processes in the animal kingdom (Aktipis & 
Nesse, 2013; Thomas et al., 2017). This especially applies to trans-
missible cancers, which can threaten the survival of species and 
raise the question of the extent to which they can be considered 
to be a separate species from their hosts (Russell et al., 2018). Just 
as with other animals, the evolution of humans was likely shaped 
by cancer (Boutry et al., 2020; Kang & Michalak, 2014; Thomas, 
Giraudeau, Renaud, et al., 2019). The environments in which hu-
mans now live and the associated lifestyle changes have undergone 
dramatic alterations since prehistoric times (Greaves & Aktipis, 
2016). Humans have been living to older ages (Gurven & Kaplan, 
2007), and incidences of cancer have therefore also increased 
(Nesse, 2005). Since most cases of cancers exert their negative ef-
fect on survival in the post- reproductive stage, the effect of fitness 
is often minimal so that natural selection will be rather ineffective 
at decreasing cancer's negative impact. Combining the knowledge 
of comparative oncology with the evolutionary ecology principles 
of multicellular organisms and ecosystem functioning will have im-
plications for not only cancer treatment but also conservation biol-
ogy given our changing, often increasingly polluted, world (Dujon 
et al., 2020; Hamede et al., 2020). Thus, the interdisciplinary field 
of research, Ecology, Evolution and Cancer, is not only transforming 
our understanding of cancer and the strategies to prevent and to 
cure it, but it also sheds light on the major influence of oncogenic 
processes on the interactions between biotic and abiotic compo-
nents of ecosystems.
2  | METHODS
We adapted the protocol previously used to identify 100 fundamen-
tal questions in ecology (Sutherland et al., 2013). We initially identi-
fied and selected established leading experts in the field based on 
their publication records and the extent of their work in the study 
of ecology and evolution of cancer, and contacted them by email. 
In addition, the participants were allowed to suggest additional 
experts who were also selected based on the same criteria. Each 
participant was invited to provide a list of the five most fundamen-
tal questions of the respective discipline, ranked by decreasing im-
portance. Each participant also provided a short highlight of up to 
150 words, and relevant references, detailing why each question is 
of key importance for the field. All questions from the participants 
were then compiled by three independent researchers, and similar 
responses were processed into a single question. Then, the most 
common questions from this list were identified and reduced to a 
total of 84 which were grouped into nine major themes (Figure 1). 
The nine major themes were first defined by the three researchers 
that compiled the responses to the questions and are presented in 
order of increasing spatial scales, ranging from the size of a cell up 
to whole ecosystems. The nine themes were then sent to all authors 
to be validated. In addition, a small literature review was also cre-
ated for each of the nine themes based on the expert summaries 
provided by the respondents. The full list of questions is provided 
as Appendix S1.
3  | RESULTS
3.1 | Major theme 1: Cancer initiation and 
progression
The recent comprehensive genomic characterization of tumours by 
the Pan- Cancer Analysis of Whole Genomes (PCAWG) Consortium, 
a great example of efficient scientific collaboration, gave insights 
into some of the underlying mechanisms driving cancer initiation and 
F I G U R E  1   The nine overarching 
eco- evolutionary questions based on key 
ecological and evolutionary concepts to 
answer in the years to come to obtain new 
insights on cancer
4  |     DUJON et al.
progression (Campbell et al., 2020; Cieslik & Chinnaiyan, 2020), and 
potentially provides support for the ‘punctuated and stepwise evo-
lution’ theory. Briefly, PCAWG demonstrated chromothripsis (when 
clustered structural variants arise in a single catastrophic event) 
to frequently be an early event in tumour evolution (see Campbell 
et al., 2020 for proportion details across a range of cancer type), and 
highlighted the importance of driver mutations, in both coding and 
non- coding regions (Campbell et al., 2020; Li et al., 2017; Rheinbay 
et al., 2020). By applying molecular clocks to classify clonal and sub-
clonal mutations, Gerstung et al. (2020) found that highly recurrent 
driver mutations and copy- number gains in particular tumour types 
tend to occur the earliest in a given cancer type (Li et al., 2017), and 
they also tend to precede diagnosis by many years, if not decades. 
PCAWG also identified characteristic genomic aberrations, called 
signatures, arising from defective DNA- repair mechanisms or expo-
sure to environmental mutagens (Alexandrov et al., 2020; Gerstung 
et al., 2020).
These recent large- scale genome and transcriptome studies of tu-
mour genomes clearly show that cancer initiation is not a step- by- step 
process simply driven by the sequential accumulation of mutations but 
rather a dynamic evolutionary process that depends on microenviron-
mental and complex genomic and epigenetic landscapes. As proposed 
by Gatenby et al. (2020), cells in multicellular organisms are involved in 
the cooperative functioning of the organism and the host is the unit of 
natural selection. Once mutations accumulate, cancer cells are able to 
abrogate control by local tissue constraints and become free from host 
constraints, and their newly acquired individual fitness is determined 
by the Darwinian interactions of their phenotype with critical prop-
erties of their local environment. Mutations previously accumulated 
over the lifetime of the host serve as their genetic heritage in their 
malignant trajectory and allow for somatic selection to favour the most 
adapted cell lines (e.g. to their local microenvironment).
Dynamic epistatic and pleiotropic processes further increase the 
enormous variation in cancer risk per (stem) cell division, both be-
tween tissues and between species (Caulin & Maley, 2011; Noble 
et al., 2015). Ultimately, cancer cells form tumours comprising dif-
ferent specialized cell populations (Aktipis et al., 2015); however, 
many cancer cells lose their original phenotype and acquire new 
functions. Apart from the diversity of tumour cell phenotypes (func-
tions), tumours contain a plethora of non- neoplastic cells which also 
contribute to division of labour (Barcellos- Hoff et al., 2013). Overall, 
the fitness of cancer cell lineages in a tumour is seen as a collective 
rather than an individual achievement with an ability to evolve re-
sistance to a number of known therapies (Capp, 2019; Lichtenstein, 
2019).
As cancer cells are fast proliferating cheater cells that take ad-
vantage of the benefits of multicellular tissue (e.g. blood flow) with-
out performing their original differentiated function for the host, 
cancer suppression systems (including the immune system) are 
sometimes been seen as cheater detection systems. Those systems 
prevent the emergence or limit the proliferation of cheater cells, for 
example by causing apoptotic response to DNA damage or inappro-
priate proliferation, the sequestration of rare stem cells or immune 
surveillance (Aktipis et al., 2015). By applying cooperation (game) 
theory to cancer biology (Archetti & Pienta, 2019), we can gain more 
leverage on questions about how cancer suppression systems work 
to prevent cancer initiation and progression (Aktipis et al., 2015) and 
how we can better support our innate cellular cheater detection sys-
tems to prevent cancer in the first place (Aktipis, 2020). Tumours 
are often detected years/decades after their initiation (see above), 
and overcoming this challenge will require improved understanding 
of conditions that are favourable to cancer initiation at the nascent 
stages of cheater- cell emergence. Addressing the questions raised in 
this publication could strongly help to prevent cancer development. 
For example, the obtained insight could be used to develop treat-
ments to reduce cancer initiation for people exposed to risk factors 
they cannot avoid.
3.1.1 | Questions
 1. What is the cell of origin in cancers?
 2. Can normal somatic cells evolve into cancer? Do somatic cells 
accumulate genetic mutations that would facilitate their adapta-
tion to their local environment without crossing the threshold of 
becoming malignant?
 3. How can mutant clones expand in normal tissues?
 4. How can early cancer- driving mutations be not eliminated from 
the host's genome when tumours start to evolve?
 5. Which genetic aberrations acquired in subclones during cancer 
progression confer a fitness advantage?
 6. How does division of labour drive tumour evolution?
 7. How do epistatic interactions shape cancer development?
 8. Is the inclusion of an ecological perspective required to under-
stand initiation and progression of cancers?
 9. Why do some organs develop on average more cancers than 
others?
 10. Which mechanisms explain variation in cancer risk, relative to 
lifetime number of stem cell divisions?
 11. Do particular life periods exist in which humans and animals are 
especially vulnerable to cancer initiation and why?
 12. What is the core eco- evolutionary programme that manifests 
independently in cancer patients leading to death?
 13. Can we perform an extensive evaluation of intrinsic factors 
involved in clonal cancer evolution? Can we gain a better un-
derstanding of the clonal evolution of malignant cells by an ap-
plying systems biology approach to understand the interactions 
between intrinsic factors?
 14. How does host phenotypic plasticity (e.g. life- history trait ad-
justments, compensatory responses) in response to oncogenic 
processes affect the fitness and evolution of cancer cells?
 15. How our understanding of oncogenesis and cancer progression 
can be improved by applying evolutionary and developmental 
biology paradigms to cancer evolution?
 16. What is the role of inter- and intra- clonal competition or coop-
eration in cancer initiation?
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 17. How can we integrate different sources of phenotypic variability 
towards inclusive inheritance in initiation of cancer and somatic 
evolution?
 18. Although specific cellular traits/markers distinguish benign from 
malignant tumours, what evolutionary processes determine the 
specific trajectories resulting in the two type of tumours?
3.2 | Major theme 2: Cancer metastasis
Metastasis is the process involving the detachment of malignant 
cells from the primary tumour site, their dispersal within the body 
and their colonization of secondary sites. Cancer metastasis ac-
counts for the overwhelming majority of cancer- related deaths 
(>90%), and if cancer cells did not metastasize, the majority of all 
cancers could be cured by primary therapy (the first treatment given 
for a disease, e.g. surgery) (Chaffer & Weinberg, 2011). Despite aris-
ing independently in each patient, cancer progression often follows 
a similar eco- evolutionary path, eventually manifesting as incurable 
lethal disease. Such convergent evolution across hundreds of thou-
sands of metastatic cancer patients each year necessitates an eco- 
evolutionary explanation beyond the typically cited acquisition of 
stochastic mutations giving rise to tumour cell heterogeneity. The 
movement of malignant cells from the primary tumour is considered 
to be a stochastic event (Chaffer & Weinberg, 2011; De Groot et al., 
2017; Fidler, 2003; Pienta et al., 2013), with shedding of billions of 
cancer cells required to successfully establish new tumour(s) at a 
distant tumour site, as the majority of circulating cancer cells per-
ishes, and only a very small minority of metastatic cells ultimately 
form a clinically apparent tumour (De Groot et al., 2017; Tissot et al., 
2019). Using the theoretical and experimental insights obtained by 
ecologists and evolutionary biologists who have been working on 
dispersal and migration in plants and wildlife species provides the 
great opportunity to improve our understanding of the complex 
metastatic process (e.g. by drawing a parallel with species relying on 
a stochastic environment to disperse eggs, larvae and propagules) 
(Tissot et al., 2019). Deciphering the evolutionary principles driving 
early dissemination of oncogenic cells might help to develop strate-
gies to prevent colonization of secondary sites, thereby minimizing 
metastases.
3.2.1 | Questions
19. Why do malignant cells metastasize since only a small fraction of 
cancer cells survives the metastatic cascade, and can we apply 
eco- evolutionary principles to identify the conditions and fac-
tors that inaugurate the transitioning of a somatic cell to a cancer 
cell with affinity for dispersal?
20. What are the ecological characteristics of the tumour that in-
duce dispersal from the primary tumour?
21. What is the role of the high tumour genetic heterogeneity during 
metastases formation?
22. What is a useful model to analyse the eco- evolutionary dynam-
ics of early metastatic development?
23. How can we use ecological principles such as those in biological 
control to suppress the initiation of the metastatic process?
3.3 | Major theme 3: Tumour and microenvironment
The microenvironment of cancer cells is their ecology, and so concepts 
and tools from ecology are likely to be useful for the study of the tumour 
microenvironment. Coupling appropriate evolutionary game and ecologi-
cal dynamics could potentially identify the absolute minimum resources 
cancer cells (and their population) need to survive, thus offering a novel 
avenue for therapies. Cancer cells alter their microenvironment, and re-
cent data have substantiated the view that changes/evolution of the mi-
croenvironment is mechanistically linked to drug resistance (Hirata et al., 
2015; Woolston et al., 2019). Furthermore, inflammation associated with 
changes during ageing promotes selection for cells with adaptive onco-
genic phenotypes (Barcellos- Hoff et al., 2013; Henry et al., 2015; Laconi 
et al., 2020). In addition, a number of experiments have highlighted the 
ability of a healthy microenvironment to repress oncogenic transforma-
tion through various mechanisms such as immune surveillance and main-
tenance of tissue structure via the extracellular matrix and healthy tissue 
(stroma) surrounding the tumour (Strobl et al., 2020).
However, no consensus has so far been drawn on how to de-
fine and spatially delineate the tumour environment that extends 
from the tumour to the whole organism, including associated mi-
croorganisms and toxic exposures (Laplane et al., 2018). Another 
conundrum that also remains is whether alterations of the micro-
environment observed in cancer are secondary to cancer develop-
ment, as in the example of the mutation of the JAK2 gene which 
induces alterations of the bone marrow environment (Arranz et al., 
2014), or whether microenvironmental changes occur first (e.g. 
due to chronic inflammatory conditions) and are sufficient to initi-
ate cancer development. It is also unclear how the tumour micro-
environment in metastases relates to that in the primary tumour 
and whether changes in the tumour microenvironment are trig-
gered by genetic or epigenetic events in the cancer cells (Marks 
et al., 2016; Taddei et al., 2013).
Therefore, the use of the eco- evolutionary framework and the 
clear identification of the selective pressures in the tumour micro-
environment will be of key importance to understand malignant cell 
development, dispersal and ability to evolve resistance to commonly 
used therapies.
3.3.1 | Questions
24. How does the microenvironment drive tumour progression?
25. What are the interactions between the tumour and its different 
environments?
26. How does ageing alter tissue microenvironments thereby select-
ing oncogenic cells?
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27. How and when do cancer cells adopt different ‘foraging 
strategies’?
28. To which extent is tumour heterogeneity a cause or a conse-
quence of oncogenesis?
29. What are the minimal essential resources necessary for can-
cer cell survival and can targeting them offer new therapeutic 
opportunities?
30. Given the diversity of the biological interactions inside neo-
plasms, to what extent does negative selection may operate 
during tumour evolution?
31. How to measure and quantify the reciprocal ecological and 
physiological feedbacks between host and tumours and their as-
sociation with coping strategies?
3.4 | Major theme 4: Infectious causes of cancer
It is well established that a significant proportion of human cancers, 
currently estimated to be around 20%, have an infectious causation 
(Dheilly et al., 2019; Ewald & Swain Ewald, 2014; zur Hausen, 2008). 
Infectious agents are known to abrogate barriers to cancer such 
as cell- cycle arrest, apoptosis, telomerase regulation for non- stem 
cells, cell adhesion for metastatic cancers and asymmetric division 
for stem cell cancers that block oncogenesis when they are in place 
(Ewald & Swain Ewald, 2014). In addition, infectious agents also dis-
rupt processes that retard but do not block oncogenesis, such as re-
strictions of resources, vulnerability to immunological defences and 
regulation of cell division rates (Ewald & Swain Ewald, 2014, 2019). 
As a consequence, infectious agents can promote tumour forma-
tion and malignancy and cause the death of the host (Ewald & Swain 
Ewald, 2019; Plummer et al., 2016). It is likely that the proportion 
of cancers with infectious causations is currently being underesti-
mated. For example, viruses can cause tumours in which only a low 
proportion of cells are infected (1% of tumour cells are Epstein– Barr 
virus- positive) (Ewald & Swain Ewald, 2019). If a criterion based on 
a low viral load is used to rule out an infectious cause, it is there-
fore possible that the number of cancers with underlying infectious 
agents is being underestimated due to our limited understanding of 
how symbionts drive oncogenesis (Dheilly et al., 2019; Jacqueline 
et al., 2017). Another component that has not yet been integrated 
is the influence of nonparasitic symbionts on vulnerability to and 
protection from oncogenesis. If commensalism is considered to be 
a dividing line between mutualism and parasitism on the mutualism/
parasitism continuum, this synthesis will involve an understanding of 
how mutualists and ambisymbionts (i.e. symbionts that can be para-
sitic or mutualistic depending on circumstance) may protect against 
oncogenic parasites, generate protective compounds and improve 
anti- cancer immune functions. The use of an eco- evolutionary 
framework is therefore required for understanding the joint contri-
butions of parasites, mutations, environmental hazards and genetic 
vulnerabilities on cancer initiation and progression but also the influ-
ence of nonparasitic symbionts on vulnerability to and protection 
from oncogenesis (Dheilly et al., 2019).
3.4.1 | Questions
32. How many cancers have an infectious causation?
33. What are the interactive effects of symbionts (parasites, com-
mensals and mutualists) as essential and exacerbating causes of 
cancer?
34. What are the ecological and environmental drivers affecting the 
emergence of infectious cancers?
35. What is the extent by which infectious agents can drive onco-
genesis even if the cells infected by the agents represent only a 
small portion of the tumour cells?
36. What can be learned from the eco- evolutionary approaches 
used to prevent and treat infectious diseases?
3.5 | Major theme 5: Cancer and the 
immune system
Intracellular infections have contributed to the evolution of multiple 
immune checkpoints to cope with potential threats without self- 
destruction. In 1893, Coley linked infection and cancer remission, 
and in 1970, Burnet proposed the important role of the immune 
system in policing cancer in his immunosurveillance hypothesis. 
Since these early works, the role of the immune system in cancer 
treatment has been demonstrated by the recent success of apply-
ing immunotherapy, particularly via using checkpoint inhibitors 
(Pardoll, 2012). For example, while resistance to proto- oncogene B- 
Raf (BRAF) inhibitors usually evolves in melanomas after only a few 
months of treatment, immunotherapy with checkpoint inhibitors, 
such as nivolumab and ipilimumab, is able to slow down the growth 
of these tumours, to induce durable immune responses and prolong 
survival (Larkin et al., 2019). In addition, mismatch repair- deficient 
tumours (e.g. gastro- oesophageal adenocarcinomas) are highly sen-
sitive tumours to immunotherapy despite their extreme levels of 
genetic heterogeneity (von Loga et al., 2020). However, ambiguity 
remains on the role of immune system in cancer control. For exam-
ple, the more recently developed immunoediting hypothesis, which 
postulates that through three stages (elimination, equilibrium and es-
cape) the immune system iteratively selects for tumour cell variants 
with increasing capacities to survive and escape immune responses, 
is more pessimistic in assuming that tumour evolution breaks down 
initial immune system control (Dunn et al., 2002). Furthermore, only 
a subset of patients responds to immune checkpoint blockade in 
melanoma and lung cancers, and the critical features that determine 
response remain unclear (Koyama et al., 2016; Zaretsky et al., 2016). 
Previous studies have suggested that neoantigens deriving from 
somatic alterations (Rizvi et al., 2015), particularly those that are 
clonal in origin (Mcgranahan et al., 2016), may be principal targets 
for immune cells, such as CD8+ T cells. However, as every tumours 
present neoantigens that are unique to the cancer but also to the in-
dividual, developing broad- spectrum and efficient immunotherapies 
remains a challenge. For example, compared with low heterogeneity 
tumours that present high clonal neoantigen burden, tumours with 
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higher- neoantigen heterogeneity may have a lower antigen dosage. 
This will further hinder treatment strategies as T cells reactive to 
specific subclonal neoantigens may be able to target only some, but 
not all cells in a tumour; moreover, identifying T cells reactive to 
very specific subclonal neoantigens can be a challenge (Rizvi et al., 
2015). We also lack the full understanding of the temporal varia-
tion of immune responses to malignant cell development and pro-
gression throughout the life of an organism (as immune response to 
tumours is often measured only after cancer diagnoses, which tend 
to be made late during tumour development). More generally, we 
are still missing critical comparative analyses of immunosuppression 
across the Tree of Life. Overall, how the immune system actively 
sculpts tumour development and, reciprocally, how a patient's im-
mune system is influenced by cancer evolution still remain unclear 
(Rosenthal et al., 2019). Also, from an evolutionary perspective, we 
cannot exclude the possibility that natural selection has adaptively 
optimized our immune system for only partially eradicate malignant 
cells (Thomas et al., 2018). Indeed, with the same logic than the one 
used in adaptive therapy (Gatenby et al., 2009), a restrained natural 
immune response would forestall immune- resistant cancer cells and 
produce long- term durable control of the cancer population.
3.5.1 | Questions
37. What are the roles of immunological checkpoints and tolerance 
in oncogenesis?
38. What are the key dynamics in the interactions of cancer cells and 
the host immune system?
39. What is the role of the immune system in shaping mutational 
landscapes and somatic evolutionary trajectories that lead to 
cancer?
40. How can we best harness a patient's immune system to tackle 
cancer evolution?
41. Why can immunotherapy (e.g. immune checkpoint inhibitors) 
seemingly cure even heterogeneous and rapidly evolving tu-
mours against which other drug therapies rapidly fail due to re-
sistance development and how we use these insights to design 
conventional therapies that are as effective?
42. Can we develop vaccines against early metastatic cells?
43. Does immune policing increase in large, long- lived animals?
3.6 | Major theme 6: Using eco- evolutionary 
principles to improve existing cancer 
prevention and treatments
Cancers evolve in response to the selective pressures of our inter-
ventions. This implies that we will need to use principles from evolu-
tion (and ecology) to manage the ever- evolving target of a cancer. 
A solid tumour is not simply a mass of cancer cells but is occupied 
by many interacting cell types (Barcellos- Hoff et al., 2013). Cancer 
cells are ecosystem engineers, altering the ecosystem of the invaded 
healthy organ and able to evolve resistance to conventional thera-
pies and develop into a hyperprogressive disease with consequences 
that lead to the death of the patient and of the cancer (Hansen et al., 
2017; Sabio & Chan, 2019). Several factors such as population size, 
mutation mechanisms and rates as well as the strength of selection 
pressure are proposed to influence how rapidly a cancer cell popula-
tion evolves (Lipinski et al., 2016; Salgia & Kulkarni, 2018). In the last 
10 years, single- cell analyses have also provided key evidence for the 
importance of non- genetic heterogeneity in cancer evolution and 
drug resistance (Navin et al., 2011). Especially, phenotypic plasticity 
produced by gene expression variability has been associated with 
important phenomena such as persister cells (Ramirez et al., 2016), 
apoptosis (Spencer et al., 2009), stemness (Patel et al., 2014) or me-
tastasis (Nguyen et al., 2016). At the same time, next- generation 
sequencing and cancer genome programmes revealed the degree 
of genetic inter- and intratumoral heterogeneity and fostered our 
understanding of tumour evolution at the genetic level (Burrell et al., 
2013), see above. In order to design effective cancer therapies, we 
need to know the proportion of subpopulations of cancer cells differ-
ing in their resistance mechanisms. For example, there are three cell 
types in metastatic castrate- resistant prostate cancer populations: 
cells dependent on testosterone, cells that are able to produce tes-
tosterone and cells independent of testosterone (Zhang et al., 2017). 
For other cancer types, no such clear cancer cell subtypes have yet 
been identified, and it may be that each cell has a potential for resist-
ance as a continuous and evolving trait instead. While we may be 
able to estimate the approximate tumour composition from relevant 
biomarkers combined with volumetric information (Alix- Panabières 
& Pantel, 2014; Pantel & Alix- Panabières, 2019; Staňková, 2019), this 
may not be precise enough in some cancers to guide therapies. For 
metastatic diseases, biopsies cannot be sampled frequently enough 
and may not give us relevant information for all tumour sites. The 
way forward may be liquid biopsies (e.g. using circulating tumour 
cells and cell- free DNA; Crowley et al., 2013). However, even then 
we will probably get averaged information on cell types within the 
patient's body and not on the state of cancer cells within each of the 
tumour sites. This will be of concern if there is a high diversity among 
these different sites. In the coming years, the main challenge will be 
to integrate these various types of heterogeneity in a global picture 
of cancer evolution and to consider the respective influence of ge-
netic or/and non- genetic heterogeneity in the different steps of the 
oncogenesis process. This is a key step in designing efficient thera-
pies and reducing the likelihood that a tumour will evolve resistance 
to drug treatments. Its importance is evidenced by the tendency for 
different patients to show dramatically different responses to the 
same treatment (Sun & Yu, 2015). This integrated picture should 
allow researchers to identify when and why treatment resistance 
can be reversed, allowing certain drugs to be reused. The PCAWG 
Consortium revealed an unprecedented scale of cancer complexity 
and thus highlighted the gargantuan obstacles ahead in cancer treat-
ment (Campbell et al., 2020).
Another challenge will be to reassess the language and meta-
phors we use for cancer, and these denominations also influence the 
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way we treat cancer and how we care for patient. The war metaphor, 
for example, positions us in opposition to cancer in a way that can 
lead to ineffective prevention measures (Hauser & Schwarz, 2015), 
and possibly bias us towards overly aggressive treatments (Aktipis 
et al., 2011). Because cancer is an evolving population that can re-
spond to our treatments, and an evolutionary foe we have lived with 
since the origins of multicellularity, we need to find appropriate met-
aphors that take into account those facts and help us think about 
effective ways of approaching cancer (Aktipis, 2020).
3.6.1 | Questions
44. Which ecological and evolutionary principles can be applied to 
slow down somatic evolution and prevent or slow down cancer 
progression?
45. When is it best to aim for tumour elimination and when for 
containment?
46. Can we influence the ability of cancers to evolve in order to 
delay, reduce or stop acquisition of drug resistance?
47.  How do genetic and non- genetic heterogeneities impact cancer 
evolution and drug resistance?
48. Can evolution of resistance be reversed?
49. How can different mechanisms of resistance influence treat-
ment prospects?
50. What is the best treatment choice based on the speed of evolu-
tion of resistance in cancer cells?
51. How can we estimate accurately the eco- evolutionary state, re-
sistance level and tumours heterogeneity in vivo?
52. How can we select a treatment that addresses all heterogeneous 
tumour sites within one patient?
53. What is the contribution of cellular plasticity (as opposed to mu-
tational change) to cancer adaptation and how central is phe-
notypic plasticity in cancer and drug resistance during tumour 
progression and drug treatment?
54. How can we exploit cooperative ecosystem engineering to 
expose unique and targetable vulnerabilities of the tumour 
ecosystem?
55. To what extent comparative oncology can help to identify novel 
solutions for cancer treatments?
56. Can we effectively prevent cancer mortality by intervening with 
the proximal causes of cancer death (e.g. cachexia, cytokine 
storms)?
57. How exactly do different cancer cells compete with each other, 
and can this mechanism of competition be enhanced by therapy 
(e.g. adaptive therapy)?
58. What proportion of cancer is preventable by lifestyle modifi-
cations and how can we aid in the social change to implement 
these interventions?
59. How is the trait of evolvability selected for in the tumour eco-
system and how does it change our understanding of cancer cell 
evolution?
3.7 | Major theme 7: Conceptual and mathematical 
models of cancer development and outcomes
Mathematical modelling of cancer has been expanding in the field of 
cancer ecology and evolution as a potentially valuable tool to comple-
ment experimental research (Archetti & Pienta, 2019; Dhawan et al., 
2016; Maley et al., 2017). Indeed, with the vast quantities of informa-
tion that are currently generated, and with a vast number of conditions 
and hypotheses to be tested, including computational tools for such 
work can be indispensable. Mathematical modelling involves formal-
izing assumptions about biological processes and describing them in 
terms of either equations (classical mathematical modelling that calcu-
lates solutions to these equations subject to specific parameter values 
and initial conditions) or rules (agent- based modelling/simulations, an-
alysed as in silico experiments with elements of stochasticity) (Altrock 
et al., 2015; Anderson & Quaranta, 2008; Beerenwinkel et al., 2015; 
Bellomo et al., 2008). Mathematical models are powerful tools that 
can help both organize understanding of the biology, test hypotheses 
and identify gaps in knowledge, since a model will predict what will 
happen if the underlying assumptions hold (and if they do not match 
observations, then a gap in knowledge has been identified). Promising 
avenues include schemes based on evolutionary and ecological indi-
ces, such as applying game theory and Lotka- Volterra equations to 
cancer treatment and other mechanistic models that recapitulate evo-
lutionary dynamics or network models that investigate gene interac-
tions (Archetti & Pienta, 2019; Dhawan et al., 2016; Mair et al., 2019; 
Maley et al., 2017). However, it is not yet established whether such 
models can outperform standard prognostic methods, nor do we know 
exactly what data types are needed for forecasting. Patients can show 
dramatically different responses to the same treatment and identifying 
the correct biomarkers will assist in developing models to understand 
how individual patients will best respond to different therapies. Those 
models will then be used to maximize survival chances and minimize 
the risk of the cancer evolving into a hyperprogressive disease (where 
the treatment accelerates the progression of the cancer) (Hansen 
et al., 2017; Sabio & Chan, 2019). Furthermore, we need to remember 
that models are also as good as the assumptions that went into them, 
and thus, useful models should be created in collaboration with biolo-
gists and experimentalists.
3.7.1 | Questions
60. Can we forecast a tumour's next evolutionary step?
61.  Is the genetic model of carcinogenesis correct and do we need 
to develop alternative models to improve our ability to forecast 
tumour evolution?
62. How can game theory be utilized to understand tumorigenesis 
and potentially guide therapy?
63. Are there measures of the evolution and ecology of tumours that 
can be used to develop a classification system for tumours, so as 
to improve prediction, prognosis and management of tumours?
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64. To what extent do the widely used model systems in cancer 
research represent the ecological and evolutionary processes 
governing tumour emergence and progression and how can 
comparative oncology be used to find new research directions?
65. How can tumour ecology be used to improve the search for bio-
markers and predict patient outcomes?
66. What lessons can we learn from the evolutionary dynamics of 
species extinction for cancer therapy?
3.8 | Major theme 8: Species- specific strategies for 
cancer prevention
Cancer is a disease that arose with the evolution of multicellularity 
and has been a major force shaping ecological and evolutionary pro-
cesses in wildlife populations (Aktipis & Nesse, 2013; Thomas et al., 
2017). Multicellular organisms evolved to resolve conflicts between 
individual cells and protect the internal organization of the individual 
by using cancer suppressor systems. In many aspects, tumours can 
be viewed as new biological entities, with rapidly expanding genetic 
diversity, that are no longer integrated in the functioning of the host 
organism, especially in the original local microenvironment (Egeblad 
et al., 2011). This especially applies to transmissible cancers. While 
currently rare, there is still a major open question about how com-
mon transmissible cancers may have been in the evolution of species 
(Ujvari et al., 2016b). It is possible that they were much more com-
mon earlier during the evolutionary history of life on earth, and that 
species simply evolved mechanisms for preventing and suppressing 
potentially transmissible cancers, explaining the low number of ex-
tant transmissible cancers (Aktipis, 2020; Ujvari et al., 2016a). It is 
also likely that the evolution of humans has been shaped by can-
cer. Despite an increasing cancer incidence due primarily to lifestyle 
changes and ageing populations, the majority of people live without 
life- threatening cancer their whole life (Bissel & Hines, 2011). While 
precursor lesions or carcinoma in situ are found in a considerable 
amount of individuals, it is still poorly understood how resistance 
mechanisms evolved to constrain expansion of oncogenic cells or 
tolerance by which the lesion or carcinoma is able to reduce their fit-
ness (Thomas, Giraudeau, Gouzerh, et al., 2019; Thomas, Giraudeau, 
Renaud, et al., 2019). Genetic endowment seems to determine how 
the organism copes with harmful extrinsic (e.g. tobacco smoke, UV) 
and intrinsic (e.g. obesity) factors, how these modulate the host's 
tissues (inducing local low- grade inflammation or not) and whether 
the combination of these factors leads to oncogenic events and can-
cer evolution (Dujon, Ujvari, et al., 2020; Pham- Danis & DeGregori, 
2019; Rozhok & DeGregori, 2015). Thus, survival, selection and ex-
pansion of transformed cells apparently depend on the microenvi-
ronmental context given by the quality and quantity of damaging 
factors, duration of exposure and host genetics. Hence, a better 
understanding of the host genetics conferring resistance and/or 
tolerance to cancer is urgently needed. Prevention and treatment 
strategies should aim at maintaining tissue homeostasis to impair se-
lection for oncogenic clones.
3.8.1 | Questions
67.   What is the importance of cancer in ecosystem functioning?
68. To what extent should oncogenesis be considered as a specia-
tion process?
69. What is the relevance of tumorigenesis as a selective force in 
nature and how does it shape ecological and evolutionary dy-
namics across species?
70. How have other species evolved to reduce the risk of develop-
ing cancer (e.g. naked mole rat, elephants), and can we translate 
those to human cancer prevention?
71. Which host- related factors are key determinants for conferring 
tolerance to cancer evolution?
72. What was and is the role of humans in causing cancers in the 
wild? Do host populations evolve resistance to transmissible 
cancers, or can cancers evolve to become less pathogenic over 
time?
73. How do rapid environmental changes such as global warming, 
increased exposure to novel pathogens and toxins contribute to 
species cancer risk?
74. Will the daily exposure to pesticides by humans and wildlife 
increase drastically the prevalence of cancer within the next 
decades?
75. How will the evolution of the human species (driven by contem-
porary aspects such as changes in environment and lifespan) af-
fect the impact of cancer on human populations, and conversely, 
how will cancer impact the evolution of human species?
76. What can we learn from people who have lived long cancer- free 
lives, including those exposed to mutagens, to understand what 
makes them resistant to cancer?
77. How have transmissible and non- transmissible cancers contrib-
uted to the evolution of species on the planet?
78. Are transmissible cancers under continued selection for novelty 
(positive selection) due to genetic conflict with their host or are 
they under selection for conservation (negative selection), or are 
they simply selectively neutral?
79. Is somatic evolution driven by mutations or natural selection?
3.9 | Major theme 9: Obtain insights from 
wild species
Considering that cancer is present in most metazoan species, 
comparing how various species have responded to the fitness 
reducing effect of cancer over the aeons of evolution (with the 
help of comparative oncology and evolutionary ecology) opens 
the opportunity for this knowledge to be translated to human 
cancer therapy (Albuquerque et al., 2018). These approaches 
include deciphering why species under significant environmen-
tal stress do not develop cancer (including long- lived humans, as 
mentioned above). This is a challenging task because cancer is dif-
ficult to detect in wildlife species and requires the development 
of new biological markers, and cancer risk factors can be difficult 
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to quantify (Dujon, Ujvari, et al., 2020; Hamede et al., 2020). 
Apart from multicellular organisms, insights can also be obtained 
from bacteria and other unicellular organisms even if they do not 
develop cancer. For example, the dynamic field studying the in-
fluence of phenotypic heterogeneity on treatment outcomes in 
cancer has largely been inspired by works on microorganisms that 
have demonstrated how gene expression variability and the as-
sociated cell- to- cell heterogeneity can produce subpopulations 
with distinct behaviours of non- genetic origin (Ackermann, 2015). 
In addition, striking similarities have been observed between the 
appearance of subpopulations tolerant to environmental stress 
in microbial populations (Blake et al., 2006) and cell responses 
to therapeutic pressure in cancer cell populations (Shaffer et al., 
2017).
Finally, although currently considered to be rare (Ujvari et al., 
2016b) but see Dujon et al. (2020), transmissible cancers present 
as inter- individual metastases (Dujon, Gatenby, et al., 2020) and 
hence can provide valuable insights in order to curtail human can-
cer cell progression and dispersal. Although the conditions that 
allow transmissible cancer lineage emergence and persistence are 
not fully understood, these intriguing clonal infectious cell lines 
(that act as cancer- causing infectious agents) use similar mecha-
nisms and pathways to avoid immune recognition and elimination 
as human cancers. Translating the information about their capac-
ity to overcome challenges in and across hosts (immune recogni-
tion, survival in transit, etc.) could contribute to novel treatment 
strategies of metastatic cancers and malignancies with underly-
ing infectious aetiologies. In addition to human cancer research 
and treatment, comparative oncology can also significantly con-
tribute to the conservation of species in which cancer is a con-
cern (e.g. Tasmanian devils or sea turtles) (Hamede et al., 2020). 
Furthermore, transmissible cancers offer excellent examples of 
how scientists organized themselves into efficient collaborative 
and multidisciplinary networks to obtain insights on those dis-
eases (Dujon, Bramwell, Raven, et al., 2020).
3.9.1 | Questions
80. How much will the biology of microorganisms inform and guide 
cancer research?
81. Which are the conditions allowing transmissible cancer lineages 
to start and spread (and can it happen in humans)?
82. What can we learn from long- lived animals, or animals that are 
exposed to excess oxidative damage, UV radiation, but rarely de-
velop cancer?
83. What are the predictors (life history, physiology, environment, 
etc.) of interspecific differences in cancer prevalence and how 
can comparative oncology help to initiate new lines of research 
for cancer treatments?
84. How do we identify and develop informative cancer biomarkers 
for non- human species?
4  | CONCLUDING REMARKS
By assembling the major challenging questions and placing 
them into specific scientific context, our objective was first to 
broaden the portfolio of research directions and methods to 
stimulate novel approaches and progress at the interface of on-
cology and ecological and evolutionary sciences. In addition to 
highlighting what we know, what we do not know, and where 
we should focus our research and practice, several general con-
clusions can be drawn from this summary. First, it is clear that 
the previous traditional separation of scientific disciplines with 
different perspectives on the same biological problem urgently 
needs to be overcome in order to make headways in our under-
standing of complex processes, such as the evolutionary ecol-
ogy of host– tumour interactions. We believe that the responses 
to many current and future questions about cancer will come as 
a result of progressive and productive multidisciplinary collabo-
rations that draw on the insights and the expertise of multiple 
scientific fields. A few (so far rare) examples of successful col-
laborations already exist, for example collaboration between 
mathematicians, ecologists and clinical oncologists spearhead 
revolutionary cancer treatment strategies that successfully in-
corporate evolutionary dynamics into cancer therapy at the 
Cancer Biology and Evolution Program, Moffitt Cancer Center, 
Tampa, Florida (Gatenby & Brown, 2020). Similarly, the Cancer 
and Evolution Laboratory at the Arizona State University is re-
searching fundamental concepts in neoplastic progression and 
therapeutic resistance (Martinez et al., 2018) and the Cancer 
Ecology and Evolution international laboratory (between Deakin 
University, the University of Tasmania in Australia and the 
Centre de Recherches Écologiques et Évolutives sur le Cancer in 
France) focuses on understanding the ecological and evolution-
ary consequences of cancer in ecosystems (Dujon, Ujvari, et al., 
2020; Giraudeau et al., 2018). Second, despite major progresses, 
especially in recent years, the topic of Ecology, Evolution and 
Cancer is still in its infancy, and a much larger global research 
effort is required. We believe that the questions compiled, and 
the directions outlined in this paper will stimulate further dis-
cussions, open up avenues for novel prevention and treatment 
approaches. Although ecological and evolutionary principles 
have already provided novel insights into several cancer- related 
topics, by identifying the major themes across the crossroads of 
evolutionary and cancer biology, we provide a focused guideline 
for future research.
GLOSSARY
Neoplasia: New, uncontrolled growth of cells that is not under physi-
ologic control.
Life- history trait: Term used in evolutionary ecology sciences to de-
scribe a species' or population's reproductive strategies. It concerns 
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parameters such as the number, size and sex ratio of offspring, the 
reproduction timing, age and size at maturity and growth pattern, 
longevity and ageing. Combinations of these life- history traits create 
the life- history strategies. Life- history strategies evolve by natural 
selection, being an optimization of trade- offs between growth, sur-
vival and reproduction.
Commensalism: A biological interaction in which individuals of one 
species gain benefits, while those of the second species neither ben-
efit nor are harmed.
Eco- evolutionary: The unidirectional effects of ecological changes 
in evolutionary processes or the unidirectional effects of evolution-
ary changes in ecological processes.
Parasitism: A biological interaction in which individuals of one spe-
cies gain benefits, while those of the second species are harmed.
Mutualism: A biological interaction in which individuals from each 
species have a net benefit.
Inclusive fitness: Taking into account not only the reproductive suc-
cess of an individual or a cancer cell, but also its effects on the sur-
vival and reproductive success of its kin.
Immune checkpoint inhibitors: A type of immunotherapy drug that 
blocks immune checkpoints, which are biochemical mechanism that 
help to keep immune responses from being too strong. Examples 
of checkpoint proteins found on T cells or cancer cells include 
PD- 1/PD- L1 and CTLA- 4/B7- 1/B7- 2. When these checkpoints are 
blocked, T cells can kill more cancer cells.
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